PM IDIplus

Main information

  • Trade name:
  • PM IDIplus
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug



  • Available in:
  • PM IDIplus
  • Language:
  • English


  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 187150
  • Last update:
  • 13-11-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:


PM IDIplus

ARTG entry for

Medicine Listed


Pharmametics Products A Division of Max Biocare Pty Ltd

Postal Address

Suite 19 Level 3 / 299 Toorak Road,SOUTH YARRA, VIC, 3141


ARTG Start Date


Product category




Approval area

Listed Medicines


Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be


The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.


1. PM IDIplus

Product Type

Single Medicine Product

Effective date



Contains lactose (or words to that effect).

Derived from cow's milk.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Treatment of acne. [Warning S required]

Aids, assists or helps in the maintenance or improvement of general well-being.

Aids, assists or helps in the maintenance of general well-being

Helps maintain healthy digestive function.

Treatment of mild digestive disorders. [Warning S required]

May assist in the management of mild to moderate acne.

Aids, assists or helps in the improvement of general well-being.

Specific Indications

Enhances immune strength, helps minimize the length and severity of common illness symptoms. Provides a boost to the immune response, including

whilst in clinical care or undergoing therapy. Can decrease the rate of common infections and subsequent illness. A natural anti-oxidant and

anti-inflammatory. Promotes digestive health, assists in the management of digestive problems. Can improve intestinal absorption of nutrients, including

iron. Shown to increase iron status. Supports healthy bone. Aids in the management of acne and inflammatory conditions.

Additional Product information

Container information



Life Time




Multiple containers

Not recorded

Not recorded

Not recorded

Not recorded

Not recorded

Pack Size/Poison information

Public Summary

Page 1 of

Produced at 29.11.2017 at 02:14:44 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information

Pack Size

Poison Schedule


1. Formulation 1

Dosage Form

Capsule, soft

Route of Administration


Visual Identification

Active Ingredients

bovine lactoferrin

200 mg

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at

Public Summary

Page 2 of

Produced at 29.11.2017 at 02:14:44 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit for contact information